X4 Pharmaceuticals

X4 Pharmaceuticals | 4,895 followers on LinkedIn. A clinical-stage biopharma company focused on the development of novel therapeutics for the treatment of rare diseases. | X4 is focused on improving healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Our first-in-class, oral, small molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. A number of PIs are attributed to the improper trafficking of immune cells related to increasing signaling on the CXCR4 receptor by its ligand CXCL12.